Wu YL, Zhong W, Wang Q, et al. Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT): A randomized, Phase III trial (CTONG 1104). J Clin Oncol. 35, 2017 (suppl; abstr 8500).
Ontlastingstest mogelijk alternatief voor colonoscopie tijdens controleafspraak
sep 2024 | Maag-darm-leveroncologie